<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1664">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04337190</url>
  </required_header>
  <id_info>
    <org_study_id>COVID-ARA2</org_study_id>
    <nct_id>NCT04337190</nct_id>
  </id_info>
  <brief_title>Impact of Angiotensin II Receptor Blockers Treatment in Patients With COVID 19 (COVID-ARA2)</brief_title>
  <acronym>COVID-ARA2</acronym>
  <official_title>Impact of Previous Treatment With Angiotensin II Receptor Blockers in Patients With SARS-Cov2 Infection Admitted to the Intensive Care Unit on Survival and Severity of the Disease (COVID-ARA2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Angers</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Angers</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The actual pandemic infection related to SARS-CoV2 results in viral pneumonitis (COVID-19),
      that may, in the more severe cases, lead the patients to the intensive care unit (ICU). The
      more frequent presentation is acute respiratory distress syndrome (ARDS).

      To penetrate cells, SARS-CoV2 uses Angioconvertase type 2 (ACE2) as a cellular entry
      receptor.

      ACE2 belong to the renin-angiotensin-aldosteron system (SRAA), and ACE2 levels are directly
      modified when SRAA inhibitors are administred to patients, and ACE2 level increases
      particularely with Angiotensin II Receptor blockers (ARA2) use.

      The aim of our study is to determine ACE2 level and activity in patients with SARSCoV2
      infection admitted to the intensive care unit (ICU).

      COVID ARA2 is a propsective cohort of patient with blood sampling at the day of admission,
      day 3 and day 7.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The actual pandemic infection related to SARS-CoV2 results in viral pneumonitis (COVID-19),
      that may, in the more severe cases, lead the patients to the intensive care unit (ICU). The
      more frequent presentation is acute respiratory distress syndrome (ARDS).

      To penetrate cells, SARS-CoV2 uses Angioconvertase type 2 (ACE2) as a cellular entry
      receptor.

      ACE2 belong to the renin-angiotensin-aldosteron system (SRAA), and ACE2 levels are directly
      modified when SRAA inhibitors are administred to patients, and ACE2 level increases
      particularely with Angiotensin II Receptor Blockers (ARA2) use.

      The aim of our study is to determine ACE2 level and activity in patients with SARSCoV2
      infection admitted to the intensive care unit (ICU).

      COVID ARA2 is a propsective cohort of patient with blood sampling at the day of admission,
      day 3 and day 7.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 3, 2020</start_date>
  <completion_date type="Anticipated">December 6, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 6, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>ACE2 level change over time</measure>
    <time_frame>at the day of admission, day 3 and day 7</time_frame>
    <description>ELISA test (Higher the ACE2 level, higher the virus penetrate cells)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ACE2 activity over time</measure>
    <time_frame>at the day of admission, day 3 and day 7</time_frame>
    <description>Ratio angiotensin (1-7)/angiotensin(1/10) (Higher Ratio angiotensin (1-7)/angiotensin(1/10), higher is ACE2 activity)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality at day 28</measure>
    <time_frame>day 28</time_frame>
    <description>Mortality at day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ARDS severity</measure>
    <time_frame>from the day of admission to day 7</time_frame>
    <description>PaO2/FiO2 ratio (ARDS is severe when &lt;100, moderate when between 100 and 200, mild when &gt;200)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of mechanical ventilation</measure>
    <time_frame>from the day of admission to day 28</time_frame>
    <description>Day under mechanical ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for prone positionning</measure>
    <time_frame>from the day of admission to day 28</time_frame>
    <description>Need for prone positionning</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for extracorporeal membran oxygenation</measure>
    <time_frame>from the day of admission to day 28</time_frame>
    <description>Need for extracorporeal membran oxygenation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of paralytic agents</measure>
    <time_frame>from the day of admission to day 28</time_frame>
    <description>Need for use of paralytic agents</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for renal replacement therapy</measure>
    <time_frame>from the day of admission to day 28</time_frame>
    <description>Need for renal replacement therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for vasoactive drugs (norepinephrine, dobutamine,epinephrine)</measure>
    <time_frame>from the day of admission to day 28</time_frame>
    <description>Need for vasoactive drugs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sequential Organ Failure Assessment (SOFA) score</measure>
    <time_frame>from the day of admission to day 7</time_frame>
    <description>The SOFA score evaluates the severity of patients through 6 items: respiration (PaO2/FiO2 ratio); coagulation (platelets count); liver (bilirubin); Cardiovascular (hypotension); Central nervous system (coma glasgow score) and Renal (creatinine serum level). Score ranges from 0 to 24, a higher score indicates higher severity and probability of death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of session(s) of prone positionning</measure>
    <time_frame>from the day of admission to day 28</time_frame>
    <description>Number of session(s) of prone positionning</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of extracorporeal membran oxygenation treatment</measure>
    <time_frame>from the day of admission to day 28</time_frame>
    <description>Duration of extracorporeal membran oxygenation treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type of vasoactive drugs</measure>
    <time_frame>from the day of admission to day 28</time_frame>
    <description>Several vasoactive agents may be used: norepinephrine, dobutamine, epinephrine, vasopressin analogues...</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of vasoactive treatment</measure>
    <time_frame>from the day of admission to day 28</time_frame>
    <description>Duration of vasoactive treatment</description>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>COVID</condition>
  <condition>Acute Respiratory Distress Syndrome</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>blood sampling</intervention_name>
    <description>blood sampling at the day of admission, day 3 and day 7</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood sample for measurement of ACE 2 level and ACE 2 activity (ratio
      Angiotensin(1-7)/Angiotensin(1-10))
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Participants :

          -  will be admitted to the ICU for respiratory failure in a context of proven COVID.

          -  will be, or not, treated for chronic hypertension,

          -  will need, or not, mechanical ventilation.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  admission to the intensive care unit,

          -  with a proven COVID infection, responsible for acute respiratory failure

          -  agree with participation to the study.

        Exclusion Criteria:

          -  aged under 18

          -  under legal protection

          -  pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre Asfar, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Angers, service de médecine intensive réanimation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pierre Asfar, MD, PhD</last_name>
    <phone>+33241355865</phone>
    <email>piasfar@chu-angers.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Julien Demiselle, MD</last_name>
    <phone>+33241355865</phone>
    <email>julien.demiselle@chu-angers.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Angers</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julien Demiselle, M.D.</last_name>
      <phone>33 (0)241355865</phone>
      <email>julien.demiselle@chu-angers.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 3, 2020</study_first_submitted>
  <study_first_submitted_qc>April 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 7, 2020</study_first_posted>
  <last_update_submitted>April 8, 2020</last_update_submitted>
  <last_update_submitted_qc>April 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

